Literature DB >> 28063800

Gene therapy for heart failure.

Barry Greenberg1.   

Abstract

Novel strategies are needed to treat the growing population of heart failure patients. While new drug and device based therapies have improved outcomes over the past several decades, heart failure patients continue to experience amongst the lowest quality of life of any chronic disease, high likelihood of being hospitalized and marked reduction in survival. Better understanding of many of the basic mechanisms involved in the development of heart failure has helped identify abnormalities that could potentially be targeted by gene transfer. Despite success in experimental animal models, translating gene transfer strategies from the laboratory to the clinic remains at an early stage. This review provides an introduction to gene transfer as a therapy for treating heart failure, describes some of the many factors that need to be addressed in order for it to be successful and discusses some of the recent studies that have been carried out in heart failure patients. Insights from these studies highlight both the enormous promise of gene transfer and the obstacles that still need to be overcome for this treatment approach to be successful.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adeno-associated virus; Gene therapy; Heart failure; SERCA2a

Mesh:

Substances:

Year:  2016        PMID: 28063800     DOI: 10.1016/j.tcm.2016.11.001

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  9 in total

Review 1.  Diabetic Cardiomyopathy.

Authors:  Wolfgang H Dillmann
Journal:  Circ Res       Date:  2019-04-12       Impact factor: 17.367

2.  Assessing the Effect of Cardiac Gene Therapy Using Catheter-Based Pressure-Volume Measurement in Large Animals.

Authors:  Tomoki Sakata; Renata Mazurek; Spyros A Mavropoulos; Francisco J Romeo; Anjali J Ravichandran; Kiyotake Ishikawa
Journal:  Methods Mol Biol       Date:  2022

3.  Gene Therapy With the N-Terminus of Junctophilin-2 Improves Heart Failure in Mice.

Authors:  Jinxi Wang; Qian Shi; Yihui Wang; Logan W Dawson; Grace Ciampa; Weiyang Zhao; Guangqin Zhang; Biyi Chen; Robert M Weiss; Chad E Grueter; Duane D Hall; Long-Sheng Song
Journal:  Circ Res       Date:  2022-03-23       Impact factor: 23.213

Review 4.  Cardiac Optogenetics: 2018.

Authors:  Patrick M Boyle; Thomas V Karathanos; Natalia A Trayanova
Journal:  JACC Clin Electrophysiol       Date:  2018-02-01

Review 5.  SOCE in the cardiomyocyte: the secret is in the chambers.

Authors:  Paul Rosenberg; Hengtao Zhang; Victoria Graham Bryson; Chaojian Wang
Journal:  Pflugers Arch       Date:  2021-02-27       Impact factor: 3.657

6.  Epigallocatechingallate attenuates myocardial injury in a mouse model of heart failure through TGF‑β1/Smad3 signaling pathway.

Authors:  Keyan Chen; Wei Chen; Shi Li Liu; Tian Shi Wu; Kai Feng Yu; Jing Qi; Yijun Wang; Hui Yao; Xiao Yang Huang; Ying Han; Ping Hou
Journal:  Mol Med Rep       Date:  2018-03-29       Impact factor: 2.952

7.  Development of an AAV9-RNAi-mediated silencing strategy to abrogate TRPM4 expression in the adult heart.

Authors:  Rebekka Medert; Andreas Jungmann; Staffan Hildebrand; Martin Busch; Dirk Grimm; Veit Flockerzi; Oliver J Müller; Patrick Most; Dagmar Schumacher; Marc Freichel
Journal:  Pflugers Arch       Date:  2021-02-13       Impact factor: 3.657

Review 8.  Cardiac T-Tubule cBIN1-Microdomain, a Diagnostic Marker and Therapeutic Target of Heart Failure.

Authors:  Jing Li; Bradley Richmond; TingTing Hong
Journal:  Int J Mol Sci       Date:  2021-02-25       Impact factor: 5.923

Review 9.  Pathophysiology of Calcium Mediated Ventricular Arrhythmias and Novel Therapeutic Options with Focus on Gene Therapy.

Authors:  Vera Paar; Peter Jirak; Robert Larbig; Naufal Shamilevich Zagidullin; Mathias C Brandt; Michael Lichtenauer; Uta C Hoppe; Lukas J Motloch
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.